Sbir phase i: genetically engineered dendritic cell to activate sars-COV-2 spike protein specific-t cell (covid-19)
Ended Project Grant Awarded Last action
- Award ID
- 2051522
- Recipient
-
Neyroblastgx LLC UEI D7H1LWMAP6J3
- Awarding agency
-
National Science Foundation
- Obligated
- $255,997
Award facts
- Assistance listing
- 47.084 NSF Technology, Innovation, and Partnerships
- Completion date
- Originally
- Place of performance
- Murrieta, CA, USA
Award details come from USAspending.gov.
About this award
Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program.
The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022.
The NSF Technology, Innovation, and Partnerships program seeks to advance science, engineering, and technology research and innovation leading to breakthrough technologies and solutions to national challenges. This award aims to support the development of a new cellular immunotherapy for COVID-19 through genetic engineering of dendritic cells.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $255,997 |
Quick answers
Who received award 2051522?
2051522 was awarded to Neyroblastgx LLC by National Science Foundation on April 1, 2021.
How much is award 2051522 worth?
$255,997 has been obligated on 2051522.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award